Biomarkers of Toxicity and Resistance
Treatment toxicities and resistance often share overlapping biology, including inflammation, immune activation, and tissue-specific vulnerability. Our lab investigates biomarker signals that reflect both toxicity risk and therapeutic response, helping to clarify which biological pathways contribute to favorable anti-tumor immunity versus harmful off-target immune effects. We examine clinical laboratory values, immune-related markers, and longitudinal biologic measures that may provide early evidence of toxicity development.
We also study biomarkers that link toxicity and resistance across treatment regimens, including immunotherapy combinations and targeted therapies. This research aims to improve understanding of the mechanisms behind treatment intolerance and incomplete response—and to support strategies that preserve efficacy while reducing harm. Ultimately, identifying biomarkers of toxicity and resistance can guide smarter treatment sequencing, safer combinations, and more personalized surveillance.